

June 2013 DUR BOARD PDL Meeting Minutes

Date: June 26, 2013

Members Present: Sather, Bradley, Brown, Burton, Caldwell, Crichton, Fitzgerald, Harrison, Cobb (phone).

Others Present: Dan Peterson, Dave Campana, Katie Hawkins (Medicaid), Kathy Novak (Magellan), Woodmansey and Barnhill (Drug PA/CM unit), Bobbi Renner and Linda Nelson (MHSP) and various members of the public and representatives of drug manufacturers.

Lisa called the meeting to order. She briefly reviewed the protocol for testimony at the PDL meetings.

Public Comment Period: Several members of the public offered comments to the Board at this time. The May DUR Board meeting minutes were reviewed and approved.

Department Update:

Beginning October 1, The Pharmacy Program for the Health Montana Kids moves claims processing from Blue Cross to the Medicaid pharmacy claims processor Xerox. This plan modification provides opportunities for local pharmacies: seamless transition when using the new BIN, PCN, and group number; the Medicaid Dispensing fee and reimbursement methodology will be used for 20,000 Montana Children; for clients there will no longer be any co-pay; the plan will follow the Medicaid regulations and the preferred drug list.

As mentioned previously, the Department is requiring pharmacies to complete a dispensing fee survey. Notice of this survey will be emailed or mailed to all pharmacies in early July. The survey may be completed online. It must be completed by August 15, or the pharmacy risks a change in their dispensing fee to \$ 2.00.

Effective 7-1-2013, the new preferred and generic dispensing fee increases to \$ 6.52, if the pharmacy's cost of dispensing supports this level.

Effective 7-1-2013, pharmacists may bill for and receive reimbursement for vaccine administration fee when administering vaccines to Medicaid clients.

PDL Review:

The Department reviewed the following classes as **NEW** information is known to exist. The Board made the following recommendations to the Department:

- ANTICOAGULANTS- Grandfathered category
 - Must have 1 LMWH, warfarin, and 1 of either apixaban, dabigatran, or rivaroxaban. Add appropriate criteria per FDA labeling.
- ANTIDEPRESSANTS, OTHER – Grandfathered category
 - Must have bupropion XL, trazodone, mirtazapine, venlafaxine ER, and may add others. Cymbalta was moved to the Neuropathic Pain category.
- ANTIDEPRESSANTS, SSRI - Grandfathered category
 - Class effect
- ATYPICAL ANTIPSYCHOTICS- Grandfathered category
 - Must have aripiprazole, risperidone, quetiapine, olanzapine and ziprasidone. May add others. Review criteria for injectables in August.
- BONE RESORPTION SUPPRESSION & RELATED AGENTS- Not grandfathered.
 - Calcitonins-Class effect. Review criteria for use at a future DUR meeting due to FDA warnings.
 - Bisphosphonates & Bone Resorption, others- Class effect for bisphosphonates, others are therapeutic alternatives.
- HEMATOPOIETIC AGENTS- Not grandfathered
 - Therapeutic alternatives
- IRRITABLE BOWEL- New Category - Grandfather existing patients
 - Therapeutic alternatives-discuss criteria at a future DUR meeting.
- NSAIDs- New Category- Grandfather by molecule
 - Class effect. Continue current criteria.

- NEUROPATHIC PAIN- New Category- Grandfathered category
 - Must have duloxetine, gabapentin, pregabalin; May add others; Lidoderm may be approved for PHN. Continue existing specific PA criteria.
 - Recommendation that drugs be posted in multiple appropriate locations on the PDL
- OPHTHALMIC ANTIBIOTIC-STEROID COMBOs- New Category-Not grandfathered
 - Steroids-Therapeutic alternatives
 - NSAIDs-Class Effect
- OPHTHALMIC ANTI-INFLAMMATORIES- New Category-Not grandfathered
 - Class effect.
- OPHTHALMIC GLAUCOMA AGENTS- Not grandfathered (all classes)
 - ALPHA 2 ADRENERGIC AGENTS-Must have brimonidine; May add others.
 - BETA BLOCKERS-Class effect.
 - CARBONIC ANHYDRASE INHIBITORS -Must have one single agent; May add others.
 - PROSTAGLANDINS -Class effect. Must have diagnosis of glaucoma (criteria currently in place)
- OTIC ANTI-INFECTIVES & ANESTHETICS- New Category-Not grandfathered
 - Therapeutic alternatives; Must have one agent with a corticosteroid.
- PLATELET INHIBITORS- Grandfather
 - Must have ASA and Aggrenox; May add dipyridamole; Class effect for clopidogrel, prasugrel and ticagrelor -Must have 1.
 - Additional information on conversion of dipyridamole plus aspirin to Aggrenox will be discussed at a future DUR Board meeting.
- SEDATIVE HYPNOTICS
 - Therapeutic alternatives; must have 1 benzodiazepine, and 1 BZ-1 selective agent; May add others
 - Revisit dosing recommendations on zolpidem at a future DUR Board meeting
- VAGINAL ESTROGEN PREPARATIONS-New category- Grandfathered
 - Therapeutic alternatives
- ADHD/CNS STIMULANTS – Trial of 2 preferred agents required; Grandfathered category
 - Must have 1 long acting agent and 1 short acting agent; May add others
- OPHTHALMIC ALLERGIC CONJUNCTIVITIS- Category expansion-Not grandfathered
 - ANTIHISTAMINES- Class effect
 - MAST CELL STABILIZERS – Class effect

The Department proposed no changes to the Formulary Committee's previous clinical recommendations.

(The following classes were not reviewed because no **NEW** information was submitted)

The Board made the following recommendations to the Department:

- ANDROGENIC AGENTS, TOPICAL- Not Grandfathered
 - Class effect
- ANTIHYPERURICEMICS – Not Grandfathered
 - Must have allopurinol; Must have colchicine with criteria for appropriate use; May add others. Uloric will continue with existing criteria.
- ANTIMIGRAINE AGENTS – Grandfathered category
 - Must have one nasal spray, must have one injectable and must have one short acting agent; May add a long acting agent. Short acting agents have a class effect.
- GROWTH HORMONES – Grandfathered Category; Therapeutic alternatives
- LONG ACTING NARCOTICS- Grandfathered category
 - Must have one long acting morphine or oxycodone; May add others
- OPHTHALMIC ANTIBIOTICS- Class effect.
- OTIC ANTIBIOTICS AND COMBOs- Class effect.
- PHOSPHATE BINDERS – Class effect.
- SKELETAL MUSCLE RELAXANTS

- Must have baclofen; other agents are therapeutic alternatives.

There were no green classes for this meeting

The next DUR Board meeting will be in August at MPQHF. Lisa will poll Board for the date.

Meeting adjourned at 4:45